RayKnowChina Research Map
Shortlist

Other diseases

Myasthenia gravis

重症肌无力

A disorder of the signal between nerves and muscles, with muscle weakness that worsens with use and antibodies to the acetylcholine receptor or MuSK. It may affect only the eye muscles, or also the face, swallowing, breathing and limbs. A tumour of the thymus (thymoma) is found in a minority of cases.

Definition adapted from MeSH (US National Library of Medicine), Mao 2012

Listed in China's first national rare-disease catalogue (2018, no. 32). The catalogue lists the narrower entry “generalised myasthenia gravis”. National Health Commission 国卫医发〔2018〕10号

hospitals in mainland China
89

with a paper from 2016–2025 or a registered study

cities
39

where those hospitals are

open trials in China
38

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 23% of the world's English-language research papers on myasthenia gravis, 2021–2025 (15% in 2016–2020), and 26% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

89 hospitals in 39 cities

Order: papers led on myasthenia gravis, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 2 papers or 1 trial on myasthenia gravis, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing11
  2. Guangzhou7
  3. Shanghai7
  4. Hangzhou6
  5. Changsha4
  6. Chengdu4
  7. Jinan4
  8. Changchun3
  9. Wuhan3
  10. Zhengzhou3

Each opens myasthenia gravis in that city. 29 more cities are in the menu below.

  1. 31 papers led
  2. 28 papers led
    No open trial led
  3. 21 papers led
  4. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    20 papers led
  5. Xiangya Hospital

    中南大学湘雅医院Changsha

    20 papers led
    No open trial led
  6. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    17 papers led
  7. 16 papers led
    No open trial led
  8. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    16 papers led
  9. 13 papers led
  10. 11 papers led
    No open trial led
  11. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    11 papers led
    No open trial led
  12. 10 papers led
    No open trial led
  13. 9 papers led
    No open trial led
  14. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    9 papers led
    No open trial led
  15. 8 papers led
    No open trial led
  16. 6 papers led
    No open trial led
  17. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    6 papers led
    No open trial led
  18. 6 papers led
    No open trial led
  19. 6 papers led
    No open trial led
  20. 6 papers led
    No open trial led
  21. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    6 papers led
    No open trial led
  22. 5 papers led
    No open trial led
  23. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    4 papers led
    No open trial led
  24. 4 papers led
    No open trial led
  25. 4 papers led
    No open trial led
  26. 4 papers led
    No open trial led
  27. 4 papers led
    No open trial led
  28. First Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第一医院(浙江省中医院)Hangzhou

    4 papers led
    No open trial led
  29. 4 papers led
    No open trial led
  30. 4 papers led
    No open trial led
  31. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    4 papers led
    No open trial led
  32. 4 papers led
    No open trial led
  33. 4 papers led
    No open trial led
  34. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    4 papers led
    No open trial led
  35. 3 papers led
    No open trial led
  36. Guang'anmen Hospital

    中国中医科学院广安门医院Beijing

    3 papers led
    No open trial led
  37. 3 papers led
    No open trial led
  38. 3 papers led
    No open trial led
  39. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    3 papers led
  40. 3 papers led
    No open trial led
  41. 3 papers led
    No open trial led
  42. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    3 papers led
    No open trial led
  43. 2 papers led
  44. 2 papers led
    No open trial led
  45. Chengdu Eighth People's Hospital

    成都市第八人民医院Chengdu

    2 papers led
    No open trial led
  46. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    2 papers led
    No open trial led
  47. 2 papers led
    No open trial led
  48. 2 papers led
    No open trial led
  49. 2 papers led
    No open trial led
  50. 2 papers led
    No open trial led
  51. 2 papers led
    No open trial led
  52. 2 papers led
    No open trial led
  53. 2 papers led
    No open trial led
  54. 2 papers led
    No open trial led
  55. 2 papers led
    No open trial led
  56. Taihe Hospital

    十堰市太和医院Shiyan

    2 papers led
    No open trial led
  57. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    2 papers led
    No open trial led
  58. 2 papers led
    No open trial led
  59. 1 paper led
    No open trial led
  60. Beijing Tiantan Hospital

    首都医科大学附属北京天坛医院BeijingInternational Department

    1 paper led
    No open trial led
  61. 1 paper led
    No open trial led
  62. 1 paper led
  63. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    1 paper led
    No open trial led
  64. 1 paper led
    No open trial led
  65. 1 paper led
    No open trial led
  66. 1 paper led
    No open trial led
  67. Jing'an District Centre Hospital

    上海市静安区中心医院Shanghai

    1 paper led
    No open trial led
  68. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    1 paper led
    No open trial led
  69. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    1 paper led
    No open trial led
  70. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    1 paper led
  71. 0 papers led
    No open trial led
  72. 0 papers led
  73. 0 papers led
  74. 0 papers led
    No open trial led
  75. 0 papers led
    No open trial led
  76. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    0 papers led
  77. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    0 papers led
    No open trial led
  78. 0 papers led
    No open trial led
  79. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    0 papers led
    No open trial led
  80. Nanyang First People's Hospital

    南阳市第一人民医院Nanyang

    0 papers led
    No open trial led
  81. 0 papers led
    No open trial led
  82. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    0 papers led
    No open trial led
  83. 0 papers led
    No open trial led
  84. Shanxi Bethune Hospital

    山西白求恩医院Taiyuan

    0 papers led
    No open trial led
  85. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    0 papers led
    No open trial led
  86. 0 papers led
  87. Tianjin Huanhu Hospital

    天津市环湖医院Tianjin

    0 papers led
  88. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    0 papers led
  89. West China Second University Hospital

    四川大学华西第二医院Chengdu

    0 papers led
    No open trial led

By university or health system 39

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Fudan University

    复旦大学Shanghai

    33 papers led
    3 hospitals
  2. Central South University (Xiangya)

    中南大学湘雅Changsha

    29 papers led
    4 hospitals
  3. Sun Yat-sen University

    中山大学Guangzhou

    28 papers led
    1 hospital
  4. Capital Medical University

    首都医科大学Beijing

    26 papers led
    6 hospitals
  5. Air Force Medical University

    空军军医大学Xi'an

    22 papers led
    3 hospitals
  6. Tianjin Medical University

    天津医科大学Tianjin

    22 papers led
    2 hospitals
  7. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    17 papers led
    1 hospital
  8. Shandong First Medical University

    山东第一医科大学Jinan

    17 papers led
    5 hospitals
  9. Sichuan University (West China)

    四川大学华西Chengdu

    17 papers led
    2 hospitals
  10. Zhengzhou University

    郑州大学Zhengzhou

    14 papers led
    4 hospitals
  11. China Medical University (Shenyang)

    中国医科大学Shenyang

    13 papers led
    2 hospitals
  12. Xuzhou Medical University

    徐州医科大学Xuzhou

    13 papers led
    2 hospitals
  13. Chongqing Medical University

    重庆医科大学Chongqing

    12 papers led
    3 hospitals
  14. Harbin Medical University

    哈尔滨医科大学Harbin

    12 papers led
    1 hospital
  15. Shandong University

    山东大学Jinan

    11 papers led
    3 hospitals
  16. Soochow University

    苏州大学Suzhou

    9 papers led
    1 hospital
  17. Hebei Medical University

    河北医科大学Shijiazhuang

    8 papers led
    3 hospitals
  18. Peking University Health Science Center

    北京大学医学部Beijing

    7 papers led
    3 hospitals
  19. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    7 papers led
    4 hospitals
  20. Anhui Medical University

    安徽医科大学Hefei

    6 papers led
    3 hospitals
  21. Guangxi Medical University

    广西医科大学Nanning

    6 papers led
    2 hospitals
  22. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    6 papers led
    1 hospital
  23. Wenzhou Medical University

    温州医科大学Wenzhou

    6 papers led
    4 hospitals
  24. Jinan University

    暨南大学Guangzhou

    5 papers led
    2 hospitals
  25. Nanjing Medical University

    南京医科大学Nanjing

    5 papers led
    1 hospital
  26. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    5 papers led
    2 hospitals
  27. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    4 papers led
    1 hospital
  28. Nanchang University

    南昌大学Nanchang

    4 papers led
    1 hospital
  29. Fujian Medical University

    福建医科大学Fuzhou

    3 papers led
    2 hospitals
  30. Guizhou Medical University

    贵州医科大学Guiyang

    3 papers led
    1 hospital
  31. Jilin University

    吉林大学Changchun

    3 papers led
    2 hospitals
  32. Qingdao University

    青岛大学Qingdao

    3 papers led
    2 hospitals
  33. 3 papers led
    2 hospitals
  34. Nanjing University

    南京大学Nanjing

    2 papers led
    1 hospital
  35. 2 papers led
    1 hospital
  36. Tongji University

    同济大学Shanghai

    2 papers led
    2 hospitals
  37. Southern Medical University

    南方医科大学Guangzhou

    1 paper led
    2 hospitals
  38. 1 paper led
    1 hospital
  39. Wuhan University

    武汉大学Wuhan

    1 paper led
    1 hospital

38

open trials on myasthenia gravis in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 29 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07249632

    Age 12 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07413835

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  3. Recruiting
    Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07470151

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  4. Recruiting
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07526493

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07622342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai

  6. Recruiting
    A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2025-03
    Registry
    NCT06688435

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  7. Recruiting
    Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT06939166

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  8. Recruiting
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT07022197

    Age 18 years to 60 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  9. Recruiting
    GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07058298

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  10. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  11. Recruiting
    CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07337785

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  12. Recruiting
    Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT04535843

    Age 0 years to 90 years (registered criteria)

    Led by Huashan Hospital; 1 listed hospital as study siteShanghai

  13. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  14. Recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06249438

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  15. Recruiting
    Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06371040

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu HospitalXi'an

  16. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi

  17. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

  18. Recruiting
    Biomarkers in Autoimmune Disease of Nervous System
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06502015

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  19. Recruiting
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT07653984

    Age 20 years to 55 years; women only (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  20. Recruiting
    Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT07146425

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  21. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  22. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

  23. Recruiting
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    Phase
    Early phase 1
    Started
    2020-09
    Registry
    NCT04561557

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  24. Recruiting
    TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
    Phase
    Not given
    Started
    2019-11
    Registry
    NCT04182984

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  25. Not yet recruiting
    A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07298928

    Age Not stated to 18 years (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  26. Not yet recruiting
    Tongji NADs Cohort
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07333196

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  27. Not yet recruiting
    Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07392528

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  28. Not yet recruiting
    Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
    Phase
    Phase 1
    Started
    2026-12
    Registry
    NCT07556120

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  29. Not yet recruiting
    A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07593911

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  30. Not yet recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07676266

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  31. Not yet recruiting
    Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07714798

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  32. Not yet recruiting
    An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07818291

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  33. Not yet recruiting
    A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    Phase
    Early phase 1
    Started
    2026-12
    Registry
    NCT07917923

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  34. Not yet recruiting
    Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
    Phase
    Early phase 1
    Started
    2025-02
    Registry
    NCT06485232

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  35. Not yet recruiting
    An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06759948

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  36. Not yet recruiting
    UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06933563

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  37. Not yet recruiting
    UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06978738

    Age 18 years to Not stated (registered criteria)

    Led by Changzhou No.2 People's HospitalChangzhou

  38. Not yet recruiting
    EFG vs IVIG in TAMG
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07231523

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions